Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years.
read more
Vykat XR is the first approved drug to address the insatiable hunger associated with the rare condition.
read more
Novo has inked a licensing deal for Lexicon’s first-in-class, oral non-incretin preclinical candidate in obesity and associated metabolic disorders.
read more
DHL will acquire Cryoport’s CRYOPDP, a specialty courier providing logistics services for clinical trials, biopharma and cell and gene therapies.
read more
The CDMO is adding a commercial-scale spray dryer and a Gerteis dry granulation system at its facility in Gainesville, Georgia.
read more
Pittsburgh-based generic drugmaker has reached a nationwide settlement framework to resolve opioid-related claims against the company and its subsidiaries.
read more
Specialty chemicals supplier Azelis has acquired Barcelona-based Solchem Nature, reinforcing its presence in the Spanish nutraceuticals market.
read more
Fexuclue is a novel potassium competitive acid blocker approved as a new treatment for adults with erosive esophagitis of all grades.
read more
Rinvoq is the first and only oral JAK inhibitor approved in the EU, Iceland, Liechtenstein and Norway, for the treatment of adult patients with GCA.
read more
The five-year investment was promised with the goal of “ensuring all key Novartis medicines for U.S. patients will be made in the United States.”
read more
The decision comes after a single participant in one of the dose-optimization studies experienced a potential drug-induced liver injury.
read more
Merck will gain non-exclusive global rights to Cyprumed’s oral peptide delivery platform for an undisclosed number of targets.
read more
Orforglipron is the first oral GLP-1, taken without food and water restrictions, to successfully complete a phase 3 trial.
read more
The new space enhances the company’s consumer health production capabilities, adding eight new product packaging lines and automated systems in logistics.
read more
Roche has joined a host of drugmakers who have announced similar initiatives amid concerns about the impact of possible tariffs on imported pharma goods.
read more